{"pii": "S237277052300058X", "abstracts": {"#name": "abstracts", "$": {"xmlns:ce": true, "xmlns:dm": true, "xmlns:sb": true}, "$$": [{"#name": "attachments", "$$": [{"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S237277052300058X-fx1.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S237277052300058X/fx1/DOWNSAMPLED/image/jpeg/4980bf9b9366f1a8d9c3b0c85029ffe5/fx1.jpg"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "43116"}, {"#name": "pixel-height", "_": "375"}, {"#name": "pixel-width", "_": "375"}, {"#name": "attachment-type", "_": "IMAGE-DOWNSAMPLED"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S237277052300058X-fx1.sml"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S237277052300058X/fx1/THUMBNAIL/image/gif/8a9911d3e02d2672b293b68b6f2b42ed/fx1.sml"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1.sml"}, {"#name": "extension", "_": "sml"}, {"#name": "filesize", "_": "8357"}, {"#name": "pixel-height", "_": "164"}, {"#name": "pixel-width", "_": "164"}, {"#name": "attachment-type", "_": "IMAGE-THUMBNAIL"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S237277052300058X-fx1_lrg.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S237277052300058X/THUMBNAIL/image/jpeg/04437aae07fd15fb3bb0d41019c62dd9/fx1_lrg.jpg"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1_lrg.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "190566"}, {"#name": "pixel-height", "_": "996"}, {"#name": "pixel-width", "_": "996"}, {"#name": "attachment-type", "_": "IMAGE-HIGH-RES"}]}]}, {"#name": "abstract", "$": {"id": "abs0010", "view": "all", "class": "author"}, "$$": [{"#name": "abstract-sec", "$": {"id": "abssec0010", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0010", "view": "all"}, "$$": [{"#name": "__text__", "_": "Diffuse midline glioma (DMG) is a childhood brain tumor with an extremely poor prognosis. Chimeric antigen receptor (CAR) T\u00a0cell therapy has recently demonstrated some success in DMG, but there may a need to target multiple tumor-specific targets to avoid antigen escape. We developed a second-generation CAR targeting an HLA-A\u221702:01 restricted histone 3K27M epitope in DMG, the target of previous peptide vaccination and T\u00a0cell receptor-mimics. These CAR T\u00a0cells demonstrated specific, titratable, binding to cells pulsed with the H3.3K27M peptide. However, we were unable to observe scFv binding, CAR T\u00a0cell activation, or cytotoxic function against H3.3K27M"}, {"#name": "sup", "$": {"loc": "post"}, "_": "+"}, {"#name": "__text__", "_": " patient-derived models. Despite using sensitive immunopeptidomics, we could not detect the H3.3K27M"}, {"#name": "inf", "$": {"loc": "post"}, "_": "26\u201335"}, {"#name": "__text__", "_": "-HLA-A\u221702:01 peptide on these patient-derived models. Interestingly, other non-mutated peptides from DMG were detected bound to HLA-A\u221702:01 and other class I molecules, including a novel HLA-A3-restricted peptide encompassing the K27M mutation and overlapping with the H3 K27M"}, {"#name": "inf", "$": {"loc": "post"}, "_": "26\u201335"}, {"#name": "__text__", "_": "-HLA-A\u221702:01 peptide. These results suggest that targeting the H3 K27M"}, {"#name": "inf", "$": {"loc": "post"}, "_": "26\u201335"}, {"#name": "__text__", "_": " mutation in context of HLA-A\u221702:01 may not be a feasible immunotherapy strategy because of its lack of presentation. These findings should inform future investigations and clinical trials in DMG."}]}]}]}, {"#name": "abstract", "$": {"class": "graphical", "id": "abs0015", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0010"}, "_": "Graphical abstract"}, {"#name": "abstract-sec", "$": {"id": "abssec0015", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0015", "view": "all"}, "$$": [{"#name": "display", "$$": [{"#name": "figure", "$": {"id": "undfig1"}, "$$": [{"#name": "link", "$": {"xmlns:xlink": true, "locator": "fx1", "type": "simple", "href": "pii:S237277052300058X/fx1", "id": "aep-link-id7"}}]}]}]}]}]}, {"#name": "abstract", "$": {"class": "teaser", "id": "abs0020", "view": "all"}, "$$": [{"#name": "abstract-sec", "$": {"id": "abssec0020", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0020", "view": "all"}, "_": "DMG is a childhood brain tumor with a poor prognosis. Our study investigated a CAR T\u00a0cell therapy targeting H3.3K27M-HLA-A\u221702:01 in DMG. However, we found insufficient presentation of the H3.3K27M26-35 peptide. These findings have implications for future immunotherapy strategies in DMG."}]}]}]}}